Literature DB >> 31093599

TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.

Sara Jiayang Li1, Lourdes M Perez-Chada1, Joseph F Merola1.   

Abstract

Tumor necrosis factor a (TNF-α)-targeted therapies have expanded the therapeutic options for patients with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA) and have significantly improved patients' quality of life. Paradoxically, anti-TNF-α agents may induce psoriatic eruptions or worsen preexisting psoriatic skin disease. Currently, there is no standard approach for the management of TNF inhibitor-induced psoriasis. Here, we conduct a literature review on TNF inhibitor-induced psoriasis and introduce a novel treatment algorithm for maintaining otherwise effective anti-TNF therapy versus switching to a different class as appropriate in the management of patients with IBD, RA, psoriasis, or PsA.

Entities:  

Keywords:  TNF inhibitor-induced psoriasis; TNF-α; biologic agents

Year:  2018        PMID: 31093599      PMCID: PMC6513344          DOI: 10.1177/2475530318810851

Source DB:  PubMed          Journal:  J Psoriasis Psoriatic Arthritis        ISSN: 2475-5303


  111 in total

1.  Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia.

Authors:  E Ladoyanni; R Nambi
Journal:  J Drugs Dermatol       Date:  2005 Mar-Apr       Impact factor: 2.114

2.  Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

Authors:  S R Feldman; K B Gordon; M Bala; R Evans; S Li; L T Dooley; C Guzzo; K Patel; A Menter; A B Gottlieb
Journal:  Br J Dermatol       Date:  2005-05       Impact factor: 9.302

3.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

4.  Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.

Authors:  P P Sfikakis; A Iliopoulos; A Elezoglou; C Kittas; A Stratigos
Journal:  Arthritis Rheum       Date:  2005-08

5.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Authors:  Mark C Genovese; Jean-Claude Becker; Michael Schiff; Michael Luggen; Yvonne Sherrer; Joel Kremer; Charles Birbara; Jane Box; Kannan Natarajan; Isaac Nuamah; Tracy Li; Richard Aranda; David T Hagerty; Maxime Dougados
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

6.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.

Authors:  Alice B Gottlieb; Robert Evans; Shu Li; Lisa T Dooley; Cynthia A Guzzo; Daniel Baker; Mohan Bala; Colleen W Marano; Alan Menter
Journal:  J Am Acad Dermatol       Date:  2004-10       Impact factor: 11.527

Review 7.  Connections between psoriasis and Crohn's disease.

Authors:  David James Najarian; Alice B Gottlieb
Journal:  J Am Acad Dermatol       Date:  2003-06       Impact factor: 11.527

8.  Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.

Authors:  Marcel Flendrie; Wynand H P M Vissers; Marjonne C W Creemers; Elke M G J de Jong; Peter C M van de Kerkhof; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2005-04-04       Impact factor: 5.156

9.  Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

Authors:  Frank O Nestle; Curdin Conrad; Adrian Tun-Kyi; Bernhard Homey; Michael Gombert; Onur Boyman; Günter Burg; Yong-Jun Liu; Michel Gilliet
Journal:  J Exp Med       Date:  2005-07-04       Impact factor: 14.307

10.  Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.

Authors:  Edmund Lee; William L Trepicchio; Judith L Oestreicher; Debra Pittman; Frank Wang; Francesca Chamian; Madhav Dhodapkar; James G Krueger
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

View more
  16 in total

Review 1.  [Biologicals and small molecules for rheumatoid arthritis].

Authors:  Stephan Blüml
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

2.  A Case of Adalimumab-Induced Psoriasiform Dermatitis in an Ankylosing Spondylitis Patient: Unusual Progression after Adalimumab Retreatment.

Authors:  Ji Ha Yoon; Joon Woo Jung; Eun Joo Park; Kwang Joong Kim; Kwang Ho Kim
Journal:  Ann Dermatol       Date:  2022-10       Impact factor: 0.722

3.  Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis.

Authors:  Daniel Octavian Costache; Oana Feroiu; Adelina Ghilencea; Mihaela Georgescu; Ana Căruntu; Constantin Căruntu; Sorin George Țiplica; Mariana Jinga; Raluca Simona Costache
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

4.  Paradoxical Reactions to Biologicals in Chronic Inflammatory Systemic Diseases.

Authors:  Igor Kremenevski; Oliver Sander; Michael Sticherling; Martin Raithel; FirstName MiddleName LastName
Journal:  Dtsch Arztebl Int       Date:  2022-02-11       Impact factor: 8.251

Review 5.  Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview.

Authors:  Kyla Pagani; Danitza Lukac; Aashni Bhukhan; Jean S McGee
Journal:  Am J Clin Dermatol       Date:  2022-04-20       Impact factor: 6.233

Review 6.  The role of xenobiotics in triggering psoriasis.

Authors:  Jasna Grželj; Marija Sollner Dolenc
Journal:  Arch Toxicol       Date:  2020-08-24       Impact factor: 5.153

7.  Adalimumab-associated psoriasiform rash in an African-American patient.

Authors:  Yusuf Chao; Jake Hutto; Neil Keshvani; Una E Makris
Journal:  BMJ Case Rep       Date:  2020-09-21

8.  Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic.

Authors:  Henit Yanai; Hadar Amir Barak; Jacob E Ollech; Irit Avni Biron; Idan Goren; Yifat Snir; Hagar Banai Eran; Yelena Broitman; Maya Aharoni Golan; Elena Didkovsky; Iris Amitay-Laish; Ayelet Ollech; Emmilia Hodak; Iris Dotan; Lev Pavlovsky
Journal:  Therap Adv Gastroenterol       Date:  2021-11-08       Impact factor: 4.409

9.  The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis.

Authors:  Meiqi Yang; Weixin Liu; Qiuping Deng; Zeng Liang; Qin Wang
Journal:  Medicine (Baltimore)       Date:  2021-10-22       Impact factor: 1.817

10.  Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy.

Authors:  Sherif A Eldirany; Minh Ho; Christopher G Bunick
Journal:  Yale J Biol Med       Date:  2020-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.